Cellectis Logo.png
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
22 déc. 2023 16h30 HE | Cellectis Inc.
NEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving...
Picture1.png
Autolus Therapeutics Announces Changes to its Board of Directors
22 déc. 2023 07h00 HE | Autolus Therapeutics plc
Autolus Therapeutics Announces Changes to its Board of Directors
cargo-logo-full-color-rgb-1165px@300ppi.png
CARGO Therapeutics Reports Business Updates and Third Quarter 2023 Results
13 déc. 2023 16h05 HE | Cargo Therapeutics, Inc.
SAN MATEO, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell...
Picture1.png
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
09 déc. 2023 20h30 HE | Autolus Therapeutics plc
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
Global CAR T-cell Therapy Market
Global CAR T-Cell Therapy Market to Surpass $15 Billion by 2030, Driven by Growing Prevalence of Multiple Myeloma and Lymphoma
08 déc. 2023 08h18 HE | Research and Markets
Dublin, Dec. 08, 2023 (GLOBE NEWSWIRE) -- The "CAR T-cell Therapy Market Size, Share & Trends Analysis Report by Product (Abecma, Breyanzi), By Disease Indication (Lymphoma, Leukemia, Multiple...
cargo-logo-full-color-rgb-1165px@300ppi.png
CARGO Therapeutics Announces Scientific Advisory Board
06 déc. 2023 08h05 HE | Cargo Therapeutics, Inc.
SAN MATEO, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CRGX), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell...
Cellectis Logo.png
Monthly information on share capital and company voting rights
01 déc. 2023 16h30 HE | Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 ...
Picture1.png
Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023
15 nov. 2023 07h00 HE | Autolus Therapeutics plc
Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023
Cellectis Logo.png
Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca
15 nov. 2023 02h30 HE | Cellectis Inc.
Execution of binding subsequent investment agreement regarding contemplated additional equity investment of $140M by AstraZeneca, previously announced on November 1, 2023.Extraordinary shareholders’...
22157.jpg
Exploring CAR-T Therapy: A New Era in Cancer Treatment
14 nov. 2023 04h48 HE | Research and Markets
Dublin, Nov. 14, 2023 (GLOBE NEWSWIRE) -- The "CAR-T Therapy- Pipeline Insight, 2023" drug pipelines has been added to ResearchAndMarkets.com's offering. The research report delves into several...